EUVIMEDEUVIMED entdecken
Open Access

Organ‐Specific Efficacy of Postischemic Empagliflozin in Acute Stroke and Myocardial Infarction Using Preclinical Models

Jiajun Li iD, Wangde Dai iD, Rashid Alavi iD, Juan Carreno, Xianghong Arakaki iD, Niema M Pahlevan iD, Robert A Kloner iD

Journal of the American Heart Association · 02.06.2026 · 15 (11)

DOI: 10.1161/jaha.125.047087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 02.06.2026. Verfasst von Jiajun Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Aerospace and Mechanical Engineering University of Southern California Los Angeles CA USA. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Myocardial Infarction, Infarction, Middle Cerebral Artery. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Empagliflozin, a sodium–glucose cotransporter 2 inhibitor, has demonstrated cardioprotective and neuroprotective effects in preclinical myocardial infarction (MI) and ischemic stroke settings by reducing acute myocardial and cerebral infarction sizes. However, the optimal administration for acute protection remains unclear. Particularly, empagliflozin effects when administered after ischemia onset but before reperfusion have not been systematically evaluated for acute MI and stroke models.

Methods

Sprague–Dawley rats underwent either middle cerebral artery occlusion/reperfusion to induce acute ischemic stroke (n=25), or left coronary artery occlusion/reperfusion to induce acute MI (n=29). Empagliflozin (20 mg/kg) or saline was administered 10 minutes after ischemia onset. Outcomes included brain/heart injury sizes and cardiac hemodynamics were quantified after 3 hours of reperfusion.

Results

In the stroke model, postocclusion empagliflozin administration significantly reduced cerebral total infarct volume compared with controls (80.83±16.59 versus 164.10±26.23 mm 3 , P =0.014), corresponding to ≈50% reduction in the infarct volume percentage, while edema was unchanged. In the MI model, empagliflozin did not reduce myocardial infarct size, ischemic risk area, or no‐reflow zone when given after occlusion/before reperfusion.

Conclusions

Our findings highlight that empagliflozin, when administered after ischemia onset but before reperfusion, provides robust neuroprotection in acute ischemic stroke but fails to limit myocardial injury in acute MI. The divergent outcomes may reflect organ‐specific pathophysiology; for example, cerebral collaterals preserve residual perfusion and drug delivery, whereas limited cardiac collateralization leads to rapid necrosis and poor drug access. Clinically, these findings suggest that early postocclusion empagliflozin therapy may be beneficial in ischemic stroke, whereas comparable early administration appears insufficient in MI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesMyocardial InfarctionInfarction, Middle Cerebral ArterySodium-Glucose Transporter 2 InhibitorsNeuroprotective AgentsAnimalsRats, Sprague-DawleyDisease Models, AnimalMaleRats

Stichwörter der Autor:innen

cardioprotectionempagliflozinischemic strokemyocardial infarctionneuroprotectionsodium–glucose transporter 2 inhibitors

Substanzen

empagliflozinBenzhydryl CompoundsGlucosidesSodium-Glucose Transporter 2 InhibitorsNeuroprotective Agents

Autor:innen und Institutionen

  • Department of Aerospace and Mechanical Engineering University of Southern California Los Angeles CA USA.
  • Cardiovascular Research Institute Huntington Medical Research Institutes Pasadena CA USA.
  • Division of Cardiovascular Medicine, Keck School of Medicine University of Southern California Los Angeles CA USA.
  • Department of Medical Engineering California Institute of Technology Pasadena CA USA.

ORCID-Profile: Jiajun Li, Wangde Dai, Rashid Alavi, Xianghong Arakaki, Niema M Pahlevan, Robert A Kloner

Zitieren

APA

Li, J., Dai, W., Alavi, R., Carreno, J., Arakaki, X., Pahlevan, N. M., & Kloner, R. A. (2026). Organ‐Specific Efficacy of Postischemic Empagliflozin in Acute Stroke and Myocardial Infarction Using Preclinical Models. Journal of the American Heart Association, 15(11). https://doi.org/10.1161/jaha.125.047087

Vancouver

Li J, Dai W, Alavi R, Carreno J, Arakaki X, Pahlevan NM, et al. Organ‐Specific Efficacy of Postischemic Empagliflozin in Acute Stroke and Myocardial Infarction Using Preclinical Models. Journal of the American Heart Association. 2026;15(11). doi:10.1161/jaha.125.047087

BibTeX
@article{Li2026,
  author = {Li, Jiajun and Dai, Wangde and Alavi, Rashid and Carreno, Juan and Arakaki, Xianghong and Pahlevan, Niema M and Kloner, Robert A},
  title = {Organ‐Specific Efficacy of Postischemic Empagliflozin in Acute Stroke and Myocardial Infarction Using Preclinical Models},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1161/jaha.125.047087}
}
Kostenlos starten →